ITUS Corp. | Income Statement

Fiscal year is November-October. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
388.90
3,667.30
255.00
300.00
362.50
Cost of Goods Sold (COGS) incl. D&A
207.70
1,727.10
473.00
436.50
460.00
Gross Income
181.10
1,940.20
218.00
136.50
97.50
SG&A Expense
7,989.80
5,277.90
6,225.90
4,266.30
5,965.00
EBIT
7,808.70
3,337.70
6,443.90
4,402.80
6,075.60
Unusual Expense
1,162.00
5,061.20
5,499.10
106.20
1,547.60
Non Operating Income/Expense
-
47.60
-
-
-
Interest Expense
1,109.50
1,263.60
451.90
519.90
500.50
Pretax Income
10,080.10
9,606.30
1,379.00
5,016.40
5,009.00
Consolidated Net Income
10,080.10
9,606.30
1,379.00
5,016.40
5,009.00
Net Income
10,080.10
9,606.30
1,379.00
5,016.40
5,009.00
Net Income After Extraordinaries
10,080.10
9,606.30
1,379.00
5,016.40
5,009.00
Net Income Available to Common
10,080.10
9,606.30
1,379.00
5,016.40
7,017.80
EPS (Basic)
1.28
1.10
0.16
0.57
0.58
Basic Shares Outstanding
7,865.80
8,710.90
8,760.10
8,739.50
12,197.30
EPS (Diluted)
1.28
1.10
0.16
0.57
0.58
Diluted Shares Outstanding
7,865.80
8,710.90
8,760.10
8,739.50
12,197.30
EBITDA
7,808.70
3,023.20
6,118.60
4,044.20
5,707.10
Other Operating Expense
-
-
-
-
13.10
Non-Operating Interest Income
0.10
8.60
17.60
12.50
19.40
Preferred Dividends
-
-
-
-
2,008.80

About ITUS

View Profile
Address
3150 Almaden Expressway
San Jose California 95118
United States
Employees -
Website http://www.ituscorp.com
Updated 09/14/2018
ITUS Corp. engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body's immunological response to the presence of a malignancy. The company was founded on November 5, 1982 and is headquartered San Jose, CA.